<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ImuVert, a new biological response modifier, was evaluated for toxicity and potential efficacy in patients with <z:e sem="disease" ids="C0877373" disease_type="Neoplastic Process" abbrv="">advanced cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This agent consists of sized, labile, natural membrane vesicles associated with ribosomes derived from Serratia marcescens </plain></SENT>
<SENT sid="2" pm="."><plain>ImuVert induces enhanced in vitro macrophage and natural-killer-cell-mediated cytotoxicity, and has demonstrated antitumor activity in palpable animal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> systems </plain></SENT>
<SENT sid="3" pm="."><plain>A group of 39 patients with a variety of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, 25 men, 14 women, with a mean performance status (Karnofsky) of 80% and median age of 57 years were entered into this trial </plain></SENT>
<SENT sid="4" pm="."><plain>ImuVert was administered subcutaneously weekly for a minimum of 3 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>A total of 183 treatments were evaluated </plain></SENT>
<SENT sid="6" pm="."><plain>Flu-like systemic toxicities, including <z:hpo ids='HP_0001945'>fever</z:hpo>, chills, <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo> and <z:hpo ids='HP_0002615'>hypotension</z:hpo> were observed </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0010783'>Erythema</z:hpo>, induration and tenderness developed at the injection sites </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">Myelosuppression</z:e>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:mp ids='MP_0002531'>anaphylaxis</z:mp>, rental and hepatic toxicities did not occur </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> symptoms resolved within 24 h </plain></SENT>
<SENT sid="10" pm="."><plain>Two patients with nodular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> achieved a partial response and two minor responses were seen in patients with <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> and <z:hpo ids='HP_0002861'>melanoma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>On the basis of ImuVert's biological activity, and tolerable toxicity it warrants further clinical investigation </plain></SENT>
</text></document>